Abstract: A cosmetic ink composition comprises a particulate material, a polymeric dispersant having a weight average molecular weight of less than about 20,000 daltons, and a polymeric rheology modifier. The particulate material can have a Particle Size Distribution D50 of about 100 nm to about 2,000 nm. The cosmetic ink composition can undergo controlled syneresis, forming a weak colloidal gel phase and a particle-lean, low viscosity phase, which can be printed without interventions such as agitation, mixing, or re-circulation to homogenize the composition.

Abstract: The invention provides devices and methods for adjusting particle size in nanoemulsions of fluorocarbons and perfluorocarbons (e.g., perfluoropentane and perfluorohexane) via sonication (e.g., ultrasonication).

Abstract: An iron-based alloy absorbable and implantable medical device for internal fixation. A substrate includes an iron-based alloy and degradable polymer. The mass ratio of the iron-based alloy to the degradable polymer is between 1:4 and 4:1. The weight-average molecular weight of the degradable polymer is between 150000 to 3000000, and the polydispersity index thereof is between 1 and 6. The device further includes antioxidants. The iron-based alloy is used as a load-bearing framework or reinforcement phase of the device. By adjusting the mass ratio of the iron-based alloy to the degradable polymer and the combination mode thereof, the corrosion rate of the iron-based alloy in the late period of the implantation is accelerated, and the quantity of corrosion products poorly soluble in the iron-based alloy is reduced. Adding antioxidants to the device further reduces the quantity of the corrosion products poorly soluble in the iron-based alloy.

Abstract: Silver nanoparticles made by a green synthesis method using silver nitrate and a chlorophyll derivative, such as a chlorophyllin are provided. The thus produced silver nanoparticles can have a crystalline structure and an average particle size ranging from about 10 nm to about 40 nm. The disclosed silver nanoparticles may be useful in treating, preventing, and/or reducing insect infestation of a variety of plants, particularly date palms.

Abstract: Provided is a stent comprising: a stent skeleton; and a deposition layer containing a plurality of layers deposited on the stent skeleton; each layer of the deposition layer comprising crystalline cilostazol, at least one of the plurality of layers comprising a bioabsorbable polymer, wherein elution of not more than 5% by mass of the crystalline cilostazol occurs by 24 hours after the stent is brought into contact in vitro at 37° C. with an elution medium of a phosphate-buffered sodium chloride solution containing 0.25% by mass of sodium lauryl sulfate.

Abstract: Particulate biomaterial containing particles having geodesic shapes for filling or replacement of bone tissue, and a method of making the particulate biomaterial containing particles having geodesic shapes for filling or replacement of bone tissue, made by rapid prototyping technique (RP), wherein said particles have non-prismatic, semi-spherical geodesic forms.

Abstract: Implantable materials may be used as spacers for separating tissues to reduce a dose of radioactivity received by one of the tissues. Applications include introducing a hydrogel spacer to a position between a first tissue location and a second tissue location to increase a distance between the first tissue location and the second tissue location, Further, there may be a step of administering a dose of radioactivity to at least the first tissue location or the second tissue location and/or a step of visualizing margins of the hydrogel spacer. A hydrogel spacer may comprise a polysaccharide and a radioopaque agent and may be used for fiducial marking.

Abstract: A high-efficiency anti-tumor nano-drug delivery system containing hydralazine (hydralazine-nanoparticles abbreviated as H-NPs) is provided. The drug delivery system takes hydralazine and doxorubicin combined by a ?-? bond as a hydrophobic core and takes dextran as a hydrophilic shell. The high-effective anti-tumor nano-drug delivery system containing hydralazine can increase the vascular permeability and blood perfusion of the tumor site, improve the enrichment and penetration of nanoparticles in the tumor, reduce tumor hypoxia, increase the sensitivity of the tumor to a chemotherapy drug doxorubicin, and significantly improve its anti-tumor effect by expanding the tumor blood vessels and regulating tumor microenvironment (TME).

Abstract: The present disclosure relates to a biodegradable ocular implant comprising a biodegradable polymer containing a compound such as Edonentan, or a pharmaceutically acceptable salt thereof. Also disclosed are methods of treatment of ocular diseases with the biodegradable ocular implant and methods of preparation of the same.

Abstract: The invention relates to methods for disrupting cholesterol crystals and related methods for the prevention and/or treatment of disease.

Abstract: This invention provides methods for producing a polymer particle which contains unusually high negative charges on the surface of the particle. Preferably, the polymer is pharmaceutically acceptable. The negative charges can be conferred by chemical groups such as carboxyl, sulfonate, nitrate, fluorate, chloride, iodide, persulfate, and many others, with carboxyl group being preferred. The invention also provides polymer particle produced by the methods of the invention.

Abstract: The disclosure provides, among other things, compositions that bind to and inhibit the biological activity of soluble biomolecules, as well as pharmaceutical compositions thereof. Also provided herein are a number of applications (e.g., therapeutic applications) in which the compositions are useful.

Abstract: An injectable in situ pore-forming hydrogel system and its preparation method and use are provided. The injectable in situ pore-forming hydrogel system uses an injectable hydrogel as a continuous base phase, and isolated live cells and magnesium particles are distributed in the continuous base phase, where the injectable hydrogel is a precursor or prepolymer of hydrogel, which can form hydrogel by cross-linking. The injectable in situ pore-forming hydrogel system can be used to create pores while the gel encapsulates live cells, which makes use of both the injectability and porous structures of hydrogel, which is important for the repair of cavitary, surgically difficult and irregularly defective tissues; meanwhile, magnesium particles generate magnesium ions after the former undergoes gas production and degradation, which can improve the bioactivity of the gel and aid in tissue repair.

Abstract: The present disclosure relates to glycan-modified nucleic acids, including short interfering RNA molecules. The glycan-modified nucleic acids include an oligosaccharide moiety that is bond to the nucleic acid and that contains a multiple antennary complex type N-glycan. The disclosure also relates to pharmaceutical compositions containing such glycan-modified nucleic acids, and methods for making and using such glycan-modified nucleic acids.

Abstract: A method of treating or preventing endocarditis in a human patient in need of therapy is disclosed. The method comprises identifying a patient inflicted with or being at risk of contracting Staphylococcus aureus, Enterococcus faecalis, or Enterococcus faecium; and locally delivering to or in the vicinity of a heart valve a therapeutically or prophylactically effective amount of rifampicin, daptomycin, dalbavancin, vancomycin, or gentamycin, or a combination of rifampicin, daptomycin, dalbavancin, vancomycin, and gentamycin. The method comprises treatment or prevention of a bacterial biofilms on the endocardium caused by Staphylococcus aureus, Enterococcus faecalis, or Enterococcus faecium.

Abstract: In some embodiments provided herein is a method of treating pain, the method comprising injecting into the subarachnoid space of the subject a pharmaceutical composition comprising: a) a multivesicular liposome comprising: at least one amphipathic lipid, and at least one neutral lipid; and b) an aqueous phase comprising bupivacaine phosphate, wherein the aqueous phase is encapsulated within the multivesicular liposome.

Abstract: The disclosure provides nanoemulsion compositions and methods of making and using thereof to deliver a bioactive agent such as a nucleic acid to a subject. The nanoemulsion composition comprises a hydrophobic core based on inorganic nanoparticles in a lipid nanoparticle that allows imaging as well as delivering nucleic acids. Methods of using these particles for treatment and vaccination are also provided.

Abstract: A seawater mineral extract derived from seawater having a salinity of from 3.4% Brix to 3.6% Brix, wherein the seawater mineral extract comprises a mineral salt content of at least 20% of the overall seawater extract.

Abstract: The present invention discloses a spray drying process characterized by continuous preparation and immediate spray drying of a solution comprising at least one active pharmaceutical ingredient and/or at least one excipient, and at least one solvent. The said active pharmaceutical ingredient(s) and solvent(s) are combined, alone or along with one or more excipients to form a first suspension. Said suspension is continuously fed to an intensifier pump that pushes said suspension through at least one micro-reaction chamber and/or at least one micro-channel where the suspension's solid(s) component(s) is(are) dissolved into said solvent(s) by means of high energy mixing I forced contact at micro, nano and molecular level to form a solution stream. The said solution stream is then immediately and continuously fed to the spray dryer through at least one atomization nozzle, drying said atomized stream to obtain solid particles and collecting said solid particles.

Abstract: An implant for ovarian decline is provided. The implant includes at least an engineered ovarian support cell an extracellular matrix substrate, and a delivery apparatus. In some embodiments, the at least an engineered ovarian support cell includes an engineered granulosa cell. In other embodiments, the at least an engineered ovarian support cell includes an engineered lutein cell. In other embodiments, the at least an engineered ovarian support cell includes an engineered theca cell.